Latest news with #ProlificMachines
Business Wire
21-05-2025
- Business
- Business Wire
Prolific Machines Selected to Join FDA's Emerging Technology Program, Advancing the Company's Novel Biomanufacturing Platform
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines, a biotechnology company revolutionizing biologics manufacturing, announced today that it has been accepted into the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Emerging Technology Program. This highly competitive program supports the development of innovative technologies that have the potential to transform therapeutics manufacturing. "This is a testament to the potential of our technology to unlock cheaper, faster, and higher quality protein production, particularly for difficult-to-produce therapeutics." Share Prolific Machines' selection by the FDA recognizes the novelty and promise of its Photomolecular Platform as a way to enhance biopharmaceutical manufacturing for many new and existing types of biologics. Prolific believes that 10-30% of promising novel, often more complex, targets are abandoned in early discovery due to their complexity. Complex therapeutics are expected to make up a significant share of the drug development pipeline in the near-future — up to 40% by 2030. Prolific believes its technology offers a potent solution for these types of manufacturing challenges. "We are honored to be accepted into the FDA's Emerging Technology Program," said Deniz Kent, PhD, CEO & Co-Founder, Prolific Machines. "This is a testament to the potential of our technology to unlock cheaper, faster, and higher quality protein production, particularly for difficult-to-produce therapeutics. We look forward to working closely with the FDA to advance our platform and make more therapies accessible to patients sooner and cheaper." The company's platform offers a novel approach to cellular control, utilizing light-control to revolutionize protein production. Its technology offers precise, efficient, and scalable solutions for biopharmaceutical manufacturing to solve biopharma's most complex protein manufacturing challenges, maximize titer and protein consistency and quality. Prolific recently completed the world's largest demonstration of optogenetics at 200L-scale in a stainless steel bioreactor. About Prolific Machines Prolific Machines is redefining biologics manufacturing, offering solutions from benchtop to pre-clinical scale. Founded in 2020, the Bay Area company's pioneering Photomolecular platform brings together advanced optogenetic tools and proprietary closed-loop control capabilities to solve major protein production challenges for early-stage biotechnology and leading pharmaceutical partners. The company is on a mission to create a healthier, more sustainable tomorrow and is supported by leading investors, including Ki Tua Fund, the corporate venture arm of the Fonterra Co-operative Group; Breakthrough Energy Ventures; Mayfield; SOSV; In-Q-Tel; and others. To learn more, visit And to qualify for a risk-free manufacturability assessment, or to become a research partner, contact partners@
Business Wire
15-05-2025
- Business
- Business Wire
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines, the Photomolecular platform leader, today announced the appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director. Meissonnier will leverage his more than 26 years of deep pharmaceutical and life science services expertise to help leading life science innovators leverage Prolific Machines' platform and its expertise. "With the right strategy, investment, innovation, and partnership culture, Prolific stands to be a leading accelerator of biopharma innovation, and I look forward to working with the Board, Deniz and the Prolific team to make this happen." Prolific Machines is leveraging advanced optogenetic technology and artificial intelligence to revolutionize protein production and offer precise, efficient, and scalable solutions for biopharmaceutical manufacturing. The Bay Area company's Photomolecular platform provides direct and dynamic control over any cellular function, in any cell type, to solve biopharma's most complex protein and viral vector manufacturing challenges, maximize titer and provide more consistent quality for biotherapies. Prolific recently completed the world's largest demonstration of optogenetics at 200L scale. 'We are well positioned to deliver impactful solutions to both early-stage biotechs and Big Pharma. Julien's pharma services experience will further accelerate our ability to do this,' said Deniz Kent, Ph.D., Prolific Machines' Co-Founder and CEO. 'I'm particularly excited about using light-based control to manufacture difficult-to-produce biotherapeutics, and I would encourage asset owners with this problem to reach out to us.' Meissonnier brings nearly three decades of leadership in biopharmaceuticals and life science services to Prolific Machines' Board. Most recently, he served as CSO of Catalent, a leading contract development and manufacturing organization (CDMO), where he was responsible for global product development and was a lead contributor to the company's strategic investment in and growth of services for new therapeutic modalities. Through offering novel and targeted development excellence, and drug delivery and manufacturing solutions to accelerate life science innovations, Meissonnier was instrumental in establishing Catalent as one of the largest, most impactful, and fastest-growing pharma services organizations. He is currently an independent advisor to life science investors and innovators. 'Having helped build and scale Catalent's CDMO services and capabilities over two decades, I am excited to support Prolific in leveraging its groundbreaking technology to enable some of the most complex yet promising biotherapeutics in today's development pipeline and ultimately, help them reach clinic,' said Meissonnier. 'With the right strategy, investment, innovation, and partnership culture, Prolific stands to be a leading accelerator of biopharma innovation and I look forward to working with the Board, Deniz and the Prolific team to make this happen.' About Prolific Machines Prolific Machines is redefining biologics manufacturing, offering solutions from benchtop to pre-clinical scale. Founded in 2020, the Bay Area company's pioneering Photomolecular platform brings together advanced optogenetic tools and proprietary closed-loop control capabilities to solve major protein production challenges for early-stage biotechnology and leading pharmaceutical partners. The company is on a mission to create a healthier, more sustainable tomorrow and is supported by leading investors, including Ki Tua Fund, the corporate venture arm of the Fonterra Co-operative Group; Breakthrough Energy Ventures; Mayfield; SOSV; In-Q-Tel; and others. To learn more, visit And to qualify for a risk-free manufacturability assessment, or to become a research partner, contact partners@
Yahoo
17-04-2025
- Business
- Yahoo
Prolific Machines Announces the Completion of Optogenetic Bioproduction at 200L, Marking the World's Largest Demonstration of Optogenetics to Date
The 200-liter run is also the first demonstration of optogenetics in a stainless-steel bioreactor. The milestone highlights the company's ability to deliver optogenetics benefits to biopharma partners at commercial scale. This capability accelerates Prolific's ability to solve significant protein production challenges as it expands its roster of light-controlled manufacturability offerings. EMERYVILLE, Calif., April 17, 2025--(BUSINESS WIRE)--Prolific Machines, the Photomolecular platform leader, announced the world's largest demonstration of optogenetics to date. The 200-liter run was completed at Prolific's Emeryville, CA pilot production facilities by the company's expert team of bioprocessing, optogenetic, hardware, and machine learning experts. Not only does this mark a significant scientific achievement, but supports Prolific's ability to deliver commercial-scale biomanufacturing solutions to prospective partners, from early-stage biotechs to leading pharmaceutical makers. The production run also showcases the ability of Prolific's light-inducible expression systems to precisely and reversibly control gene expression in mammalian cells. This presents a critical advantage for biologics manufacturing, especially with difficult-to-produce candidates. A Prolific-designed, plug-and-play illumination system was used to precisely control cellular activation with light. The company will continue to develop its closed-loop control systems to continuously monitor and adjust cellular activation based on real-time data. This data will also be used to determine optimal future run parameters. "We started Prolific in 2020 driven by the deep belief that light is the best way to control biology. Less than five years later, thanks to our incredible team, we are not only proving that this is true, but demonstrating that it is possible at scale," said Deniz Kent, PhD, Prolific Machine's Co-Founder & CEO. "This 200-liter milestone is really just the beginning. We are enabling a more efficient and effective biomanufacturing future driven by Prolific's driverless bioreactors. The key is creating a shared language between the machines and the cells, which is light. We believe we can bring the same level of autonomy to biomanufacturing that driverless vehicles have brought to the automotive industry." The run is yet another major step taken by Prolific to commercialize molecular optogenetics, a novel technology that uses light-sensitive proteins to drive cellular behavior. These photoreceptors are sourced from light-sensitive organisms found in nature, like plants or bacteria, and are engineered into a target cell line to control any biological function. By delivering light in specific patterns, intensities, and wavelengths, Prolific can obtain precise and dynamic cellular control across any cell type. "Not only have we transferred the ability to control cellular function with light from the research lab to commercial applications, we have now done this at scale," said Maximilian Hoerner, PhD, Prolific Machine's Head of Optogenetics and a former PI in the space. "The implications for this are significant as we work to manufacture previously unproducible biologics candidates for partners and accelerate their ability to bring these to clinic." About Prolific Machines Prolific Machines is redefining biologics manufacturing, offering solutions from benchtop to manufacturing scale. Founded in 2020, the Bay Area company's pioneering Photomolecular platform brings together advanced optogenetic tools and proprietary closed-loop control capabilities to solve major protein production challenges for early-stage biotechnology and leading pharmaceutical partners. The company is on a mission to create a healthier, more sustainable tomorrow and is supported by leading investors, including Ki Tua Fund, the corporate venture arm of the Fonterra Co-operative Group; Breakthrough Energy Ventures; Mayfield; SOSV; In-Q-Tel; and others. Visit to learn more, and contact partners@ to qualify for a risk-free manufacturability assessment. View source version on Contacts Media ContactNicki Briggs, MS, RDNVP, Communicationscomms@ Sign in to access your portfolio
